SCHEMBL5331649

SCHEMBL5331649

NC(CO)CCN1CC(Oc2ccc(Cl)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.38
SLC6A4 P31645 2/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
HTR2C P28335 1/20 0.36
KCNH2 Q12809 1/20 0.36
ESR1 P03372 1/20 0.35
S1PR5 Q9H228 1/20 0.35
ACACB O00763 1/20 0.34
HTR2A P28223 2/20 0.34
HTR7 P34969 2/20 0.34
HTR1A P08908 1/20 0.34
HTR6 P50406 1/20 0.34
FPR2 P25090 3/20 0.33
PROKR1 Q8TCW9 3/20 0.33
EPHX2 P34913 1/20 0.33
NMT2 O60551 1/20 0.33
NMT1 P30419 1/20 0.33
CHEK2 O96017 1/20 0.33
P2RX3 P56373 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5335584 0.99 SIGMAR1 (0.40) SIGMAR1SLC6A4SLC6A2SLC6A3HTR2C
Bromide SCHEMBL7255866 0.99 SIGMAR1 (0.37) SIGMAR1SLC6A4SLC6A2SLC6A3HTR2C
Hydrochloric Acid SCHEMBL5335577 0.99 SIGMAR1 (0.40) SIGMAR1SLC6A4SLC6A2SLC6A3HTR2C
SCHEMBL5331909 0.86 GRIN1 (0.42) CCR3
SCHEMBL5331901 0.86 GRIN1 (0.42) CCR3
SCHEMBL5335013 0.85 SLC6A2 (0.44) SLC6A4SLC6A2SLC6A3KCNH2FPR2
SCHEMBL5335008 0.85 SLC6A2 (0.44) SLC6A4SLC6A2SLC6A3KCNH2FPR2
Hydrochloric Acid SCHEMBL5338443 0.85 GRIN1 (0.41) CCR3
Hydrochloric Acid SCHEMBL5338438 0.85 GRIN1 (0.41) CCR3
Hydrochloric Acid SCHEMBL5332083 0.84 SLC6A2 (0.41) SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288537-B2 Azetidine derivatives as CCR-3 receptor antagonists NOVARTIS AG (CH) 2007-10-30 US disclosed
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists NOVARTIS AG (CH) 2005-10-06 US disclosed
EP-1487435-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2004-12-22 EP disclosed
WO-2003077907-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists CCR3, CCR1, CCR9 SIGMAR1 412/4885SLC6A4 1121/4885SLC6A2 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.